C-peptide – Medxy AI

Impact of Residual C-Peptide on Long-Term Outcomes in Type 1 Diabetes: Insights from the Scottish Cohort

By MedXY 08/11/2026

This study highlights that higher baseline and maintained C-peptide levels in type 1 diabetes are linked to reduced risks of acute complications and retinopathy, underscoring the importance of preserving endogenous insulin secretion.

Diabetes & Endocrinology news

Exploring Low-Dose Antithymocyte Globulin Therapy in Type 1 Diabetes: Real-World Insights Using Modified Quantitative Response of C-Peptide

By MedXY 07/14/2026

This article examines real-world data on low-dose antithymocyte globulin in type 1 diabetes, assessing beta-cell function via a novel C-peptide modified quantitative response (mQR). Findings suggest feasibility, safety, and potential clinical benefit in preserving endogenous insulin secretion.

Diabetes & Endocrinology news

Early Detection of β-Cell Preservation in New-Onset Type 1 Diabetes: Insights from Serial Dried Blood Spot C-Peptide Sampling in the USTEKID Trial

By MedXY 07/10/2026

Serial dried blood spot C-peptide sampling detects early β-cell preservation in new-onset type 1 diabetes more sensitively than urine C-peptide-to-creatinine ratio or mixed-meal tolerance test.

Diabetes & Endocrinology news

Beta Cell Glucose Sensitivity May Predict Response to New-Onset Type 1 Diabetes Therapies

By MedXY 06/03/2026

A pooled analysis of nine type 1 diabetes trials found that beta cell glucose sensitivity may better predict response to disease-modifying therapy than C-peptide alone, helping identify patients most likely to benefit.

Clinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Revealing Metabolic Subtypes in Gestational Diabetes Using Dynamic OGTT-Derived C-Peptide Trajectories: Implications for Personalized Risk and Management

By MedXY 08/21/2025

Dynamic C-peptide patterns during OGTT uncover metabolic heterogeneity in GDM, identifying insulin-resistant women at risk for fetal overgrowth and normoglycemic women at risk for preeclampsia, suggesting improved stratified treatment beyond glucose-based diagnosis.